Compass Therapeutics Announces Positive Phase 2/3 Study Results for Tovecimig in Biliary Tract Cancer

BOSTON, MA – April 27, 2026: Compass Therapeutics, Inc. (NASDAQ: CMPX), a clinical-stage biotechnology company focused on cancer immunotherapies, has announced statistically significant and price-sensitive clinical trial results for its lead candidate, tovecimig, in patients with biliary tract cancer (BTC). The company released these pivotal data in a randomized Phase 2/3 study (COMPANION-002), signaling a potential breakthrough for patients in the second-line treatment setting.

Key Points from the Report

• Statistically Significant Benefit: Tovecimig, when combined with paclitaxel, showed a significant improvement in objective response rate (ORR) and progression-free survival (PFS) compared to paclitaxel alone.
• Primary Endpoint: ORR was 17.1% for the tovecimig arm vs. 5.3% in the control (BICR-assessed, p=0.031).
• Key Secondary Endpoint: PFS improved dramatically, with a median of 4.7 months for tovecimig patients vs. 2.6 months for controls (HR=0.44, p<0.0001).
• Overall Survival (OS): OS analyses were confounded by high crossover rates (54% of control patients crossed over to the tovecimig arm; 85% of all study patients received tovecimig). Subset analysis showed crossover patients had significantly improved OS (12.8 vs. 6.1 months, HR=0.54, p=0.04).
• Safety Profile: Tovecimig was generally well-tolerated, with adverse events consistent with prior studies. Most common grade ≥3 AEs were anemia (44%) and neutropenia (36%).
• Regulatory Pathway: Compass intends to meet with the FDA in the coming months to discuss these data ahead of a planned Biologics License Application (BLA) submission. The company expects to present the complete dataset at a medical conference later this year.
• Webcast Event: Compass hosted a webcast at 8:00 a.m. ET to review the data, with slides and a replay available on the investor relations section of their website.

Material Information for Shareholders

• This announcement is highly price-sensitive: The demonstration of statistically significant clinical benefit in a randomized, pivotal trial positions tovecimig as a potential new treatment for BTC, a cancer with limited options. If regulatory discussions are successful, this could lead to an FDA approval—a major catalyst for CMPX shares.
• High Crossover Rates: The majority of patients ultimately received tovecimig, which may complicate OS interpretation but also underscores physician enthusiasm for the drug.
• Upcoming FDA Meeting: A successful FDA interaction and subsequent BLA submission would be a significant milestone and likely impact share price positively.
• Funding Needs: The company highlights that continued business and product development will require additional funding, a potential risk for shareholders.
• Forward-Looking Statements: While results are promising, future milestones include regulatory discussions, full dataset presentation, and further financing—each potentially affecting share value.

Additional Details

• Company Details: Compass Therapeutics, Inc. is incorporated in Delaware and headquartered at 80 Guest Street, Suite 601, Boston, MA 02135. The company trades on the NASDAQ Capital Market under the symbol CMPX.
• Leadership: The report was signed by Neil Lerner, Chief Accounting Officer.
• Exhibits: Press release and webcast presentation slides are available as Exhibits 99.1 and 99.2, respectively, in the 8-K filing.

Potential Share Price Impact

The report’s revelations are highly material to shareholders, with the potential for regulatory approval of tovecimig in BTC representing a significant value inflection point for Compass Therapeutics. The clinical data suggest a strong efficacy signal and a manageable safety profile, which—if favorably received by regulators—could make tovecimig a new standard of care for BTC. Investors should monitor upcoming FDA meetings and conference presentations for further updates.

Disclaimer

The above article contains forward-looking statements, including expectations for regulatory review, clinical development, and commercialization of Compass Therapeutics’ product candidates. These statements are subject to risks and uncertainties, including the company’s ability to raise additional funding, regulatory outcomes, and competitive market conditions. Actual results may differ materially. Investors should consult Compass’s filings with the SEC for further risk disclosures. This article is for informational purposes only and is not investment advice.

View Compass Therapeutics, Inc. Historical chart here